PORTLAND, Ore.--(BUSINESS WIRE)--HemCon today announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon’s continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology. The Onychomycosis treatment, Mycosinate™ (formerly known as compound A31S), is available for commercial license and provides a controlled release broad spectrum antimicrobial agent to fight infection.
